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RNA structural flexibility underlies fundamental biological processes, 26 
including splicing, translation, and the lifecycle of RNA viruses. However, 27 
there are no experimental or computational methods to explore the multiple 28 
conformations adopted by RNAs in vivo.  We developed Crosslinking Of 29 
Matched RNAs And Deep Sequencing (COMRADES) for in-depth conformation 30 
capture of RNA and retrieval of RNA structural ensembles. Using COMRADES, 31 
we determined the architecture of the Zika virus RNA genome inside cells, and 32 
revealed multiple interactions with human non-coding RNAs.  33 
 34 
Structure probing techniques have been proven valuable for studying cellular and 35 
viral RNA structure1–9. Inside cells however, RNA is engaged in multiple processes 36 
including splicing, translation, and regulation by RNAi, suggesting high structural 37 
plasticity. Recent methods have utilized proximity ligation to reveal RNA base-pairing 38 
within cells 10–16. Nevertheless, the ability to assess the structural plasticity of RNA 39 
and report the ensemble of coexisting conformations has not been reached, due to 40 
insufficient probing depth and lack of appropriate computational algorithms. We 41 
developed a method—Crosslinking Of Matched RNAs And Deep Sequencing 42 
(COMRADES)—that couples an improved in vivo probing of RNA base-pairing with 43 
selective RNA capturing. We additionally established an algorithm for assessing the 44 
structural complexity of RNA inside cells (Fig 1a). 45 
  46 
COMRADES utilizes a cell-permeable, azide modified, psoralen derivative 47 
(Psoralen-triethylene glycol azide) to facilitate coupling of two effective affinity 48 
capturing steps, while overcoming the limited cell permeability of biotin labelled 49 
psoralen (Supplementary Fig. 1a). The azide group does not affect the psoralen 50 
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crosslinking properties (Supplementary Fig. 1a). Following in vivo crosslinking, an 51 
RNA of interest is selectively captured, reaching enrichment level of nearly 1000-fold 52 
(Fig. 1b, Supplementary Fig. 1b-c). The RNA is then fragmented, and a copper free 53 
click-chemistry reaction links a biotin moiety to in vivo crosslinked regions, enabling 54 
a second streptavidin-based affinity selection of crosslinked regions (Fig. 1c, 55 
Supplementary Fig. 1d). The resulting RNA is split: One half is proximity ligated to 56 
create RNA chimeras, following reversal of the crosslink to enable high-throughput 57 
sequencing and assessment of the base-pairing (Fig. 1d, Supplementary Fig. 1e). 58 
The other half is used as a control, in which reversal of the crosslink precedes the 59 
proximity ligation. COMRADES and control samples contain essentially identical 60 
RNA composition, ensuring accurate assessment of artificial chimeric reads 61 
originated from random ligation or reverse transcription errors. COMRADES’s dual 62 
enrichment substantially increases structure probing depth of selected RNA, thus 63 
enabling an unbiased and global view of coexisting conformations. COMRADES 64 
yields high levels of ligated chimeric reads (8%), whereas these are kept 4 fold lower 65 
in the controls, or in a non-crosslinked samples (Fig. 1e). We successfully reported 66 
on the known ribosomal RNA structure with high sensitivity (Supplementary Fig. 2), 67 
while spurious interactions between cytoplasmic and mitochondrial ribosomal RNA 68 
subunits occurred at a very low level (Fig. 1f). The robustness of COMRADES is 69 
further demonstrated by its high reproducibility (Fig. 1g-h). 70 
  71 
RNA viruses utilize RNA base-pairing to regulate various aspects of their life 72 
cycle17–21. Inside the host cell however, the full-length architecture of RNA genomes 73 
and their interactions with the host transcriptome are largely unknown. We used 74 
COMRADES to determine RNA base-pairing along the 10.8 kilobases-long single-75 
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stranded RNA genome of Zika virus (ZIKV) from the Flavivirus genus inside human 76 
cells. We identified 1.7 million non-redundant chimeric reads corresponding to the 77 
structure of the ZIKV genome (Fig. 1g-h, Supplementary Fig. 3a). This high probing 78 
coverage is valuable for analysing multiple coexisting conformations. Previous work 79 
mainly identified RNA structures in the untranslated regions (UTRs) of flaviviruses, 80 
while leaving 95% of the genome unexplored17–21. COMRADES identified base-81 
pairing along the entire genome and between the open reading frame (ORF) and the 82 
UTRs (Supplementary Fig. 3b, 4a). Nearly 80% of the identified interactions span a 83 
distance of less than 1,000 nucleotides (nt), implying local structure with a certain 84 
degree of three-dimensional compaction (Supplementary Fig. 3c). Both short- and 85 
long-range interactions were supported by reproducible, well-defined clusters of 86 
chimeric reads, ligated in 5'-3' and 3'-5' orientations (Supplementary Fig. 3a), and 87 
showed strong evidence of base-pairing when analyzed with the hybrid-min RNA-88 
folding algorithm as compared to a shuffled-chimeras control (Wilcoxon test p-value 89 
< 0.0001). COMRADES therefore enables a deep and comprehensive analysis of 90 
RNA base-pairing. 91 
  92 
During replication, the genome of flaviviruses undergoes a global 93 
conformational change mediated by a long-distance base-pairing between the 5' and 94 
3' cyclization sequences17,18 (5' CS and 3' CS respectively), as well as the upstream 95 
and downstream of AUG regions (UAR and DAR respectively)19,20. COMRADES 96 
detected extensive and highly specific base-pairing between the known cyclization 97 
elements, therefore demonstrating genome cyclization inside cells (Fig. 2a-c, 98 
Supplementary Fig. 4b). COMRADES further refined the nature of the base-pairing 99 
associated with genome cyclization, by identifying contact regions upstream of the 5' 100 
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UAR and downstream of the 3' UAR (Fig. 2a,c). We additionally detected an 101 
alternative 5' UTR conformation where stem-loops A and B (SLA and SLB 102 
respectively) are not formed but rather engaged in long-distance base-pairing with 103 
the downstream envelope coding sequence (Fig. 2d-f). COMRADES confirmed the 104 
existence of previously defined functional RNA pseudoknots including the dumbbell 105 
(DB) pseudoknot22, the downstream of 5' cyclization sequence-pseudoknot (DCS-106 
PK)23, and the SL1 pseudoknot24 (Supplementary Fig 4c). Overall, COMRADES 107 
identified nearly all previously known flavivirus RNA structures and has further 108 
defined critical base-pairing involving the UTRs. 109 
 110 
Our intra-viral RNA-RNA interaction map revealed the presence of multiple 111 
mutually exclusive RNA structures, where one region alternately base-pairs with 112 
several other regions. The averaged Shannon entropy per nucleotide was 5.9 bits, 113 
implying high folding plasticity (Supplementary Fig. 5a). We found a strong inverse 114 
correlation between the degree of experimental support for base paired regions and 115 
their entropy (Supplementary Fig. 4a, 5b-d). To explore the ensemble of alternative 116 
structures, we developed an algorithm to computationally fold ~1,000 nucleotide-long 117 
regions using randomly selected subsets of high-confidence mutually compatible 118 
folding constraints derived from the in vivo data. For each region, a set of 1,000 119 
structures was generated. The validity of this approach is demonstrated by the clear 120 
correlation between the thermodynamic stability and the number of reads supporting 121 
each structure (Fig 2g, Supplementary Fig. 6). Nevertheless, the most 122 
thermodynamically favoured structures gained only moderate experimental support, 123 
implying the additional impact of the cellular environment on RNA folding3,4,16,25,26. 124 
  125 
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We further computed the degree of similarity between all pairs of structures 126 
and applied multidimensional scaling to cluster structures based on their similarity. 127 
The presence of separated well defined clusters reflects the occurrence of 128 
alternative conformations (Fig. 2h, Supplementary Fig. 7a). As a control, we 129 
randomly shuffled the interacting RNA partners between the chimeric reads; the 130 
resulting shuffled structures clustered separately from the structures recovered by 131 
COMRADES (Supplementary fig. 8). A single ZIKV structure typically accounted for 132 
~30% of the in vivo observed interactions, whereas a reduced set of 5 structures 133 
was sufficient to capture 80-90% of the in vivo data (Supplementary Fig. 7b). Our 134 
analysis suggests that the intracellular folding complexity of the ZIKV genome might 135 
be explained by postulating the coexistence of a small subset of alternative 136 
conformations. 137 
  138 
Viral RNAs have an inherent capacity to form specific interactions through 139 
base-pairing with host RNAs27, however little is known about the prevalence of such 140 
interactions. COMRADES revealed multiple interactions between the ZIKV genome 141 
and human small regulatory RNAs (Fig. 3a). We found site-specific interactions 142 
between the ZIKV ORF and the U1 small nuclear RNA (snRNA, Fig. 3b), plausibly 143 
affecting host splicing. We similarly detected highly site-specific interactions between 144 
the ZIKV ORF and tRNAs Glu116 and Gly34 (Fig. 3c). We identified several 145 
interactions between the ZIKV genome and human microRNAs, including miR-21, 146 
miR-19, miR-512, miR-515, and miR-1323 (Fig. 3d). While previous psoralen-based 147 
methods failed to effectively capture interactions involving miRNAs10–12, 148 
COMRADES successfully discovered miRNA base-pairing (Fig. 3a,d). COMRADES 149 
indicated non-canonical base-pairing between the 5' CS of ZIKV and the seed region 150 
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of miR-21 (Fig. 3e, adjusted p-value 1.0E-13). The miR-21 interaction with the ZIKV 151 
genome was further proved significant using an independent analysis pipeline (FDR 152 
3.0E-25, supplementary methods). In vitro synthesized miR-21 failed to bind the ZIKV 153 
5' CS on its own, while pre-loading miR-21 onto purified Argonaute2 (Ago2) 154 
facilitated a strong and sequence specific interaction (Supplementary Fig. 9), 155 
supporting the involvement of Ago2 in this base-pairing. CRISPR/Cas9 deletion or 156 
antisense inhibition of miR-21 in human cells decreased the intracellular level of the 157 
ZIKV genome (Supplementary Fig. 10a-d) or the ZIKV envelope protein 158 
(Supplementary Fig. 10e-j). Abrogating the miR-21 binding ability of a ZIKV replicon 159 
through point mutations renders it insensitive to miR-21 antisense inhibition 160 
(Supplementary Fig. 10k), indicating that miR-21 acts through direct interaction with 161 
the 5' CS. 162 
  163 
In summary, COMRADES revealed the highly dynamic nature of an RNA 164 
genome inside cells, and its ability to engage in base-pairing with multiple host 165 
regulatory RNAs. The involvement of the conserved 5' CS of ZIKV in genome 166 
cyclization, capsid translation and miR-21 binding further demonstrates the structural 167 
complexity of RNA genomes inside cells (Fig. 3f). The general applicability of 168 
COMRADES provides an opportunity to undertake a complete and unbiased 169 
analysis of the dynamic nature of RNA inside cells and can be utilized to investigate 170 
the structure and interacting partners of any cellular or foreign RNA in any species. 171 
 172 
 173 
 174 
 175 
ea
b d
Enriched
Flowthrough
Co
nt
ro
l
Cr
os
sli
nk
Input
Input
c
Enriched 
Reversed
UVC
f
Ziv et al., Fig. 1
g h
virus RNA crosslink
in-vivo RNA crosslinking crosslinked-RNA pulldown
host RNA
crosslink reversal
crosslink reversal
ligation
ligation
virus-RNA pulldown
biotinylated 
probestreptavidin 
bead
B
B
B
B
B
B
B
biotin-click
rRN
A:r
RN
A
mtr
RN
A:m
trR
NA
mtr
RN
A:r
RN
A
0
1
2
3
4
%
 o
f t
ot
al 
ch
im
er
ic 
re
ad
s
0
2
4
6
8
Ch
im
er
ic 
re
ad
s, 
%
1,
50
0 
nt
Replicate 1 Replicate 2 Replicate 3
Control 1 Control 2 Control 3
1,500 nt
 
Zi
ka
 g
en
om
e 
co
or
din
at
e 
(1
-1
0,
80
7 
nt
)
Zika genome coordinate (1-10,807 nt)
sequencing
data
list of
chimeras 
folding
constraints
randomised parallel
RNA folding
structure scoring
and clustering
776-641     3339
775-642     3339
774-643     3334
777-640     3247
4114-3985    3230
4115-3984    3230
4113-3986    3223
4116-3983    3135
4112-3987    3077
4117-3982  3043
basepair score
**
*
x 1000
*
**
Fl
uo
re
sc
en
t u
nit
s
Molecular size, nt
0
50
100
25 500 2,000
4,000
0
10
20 ZIKV
marker
25 500 2,000
4,000
18S
rRNA
28S
rRNA
CO
MR
AD
ES
Co
ntro
l
No
n c
ros
slin
ked
b c
g
SLA
SLB
cHP
5' CS
DCS
20
40
60
200
1020
1080
1100
1120
11601
806 nt
0 410
Ziv et al., Fig. 2
a
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
−200
−100
0
100
200
300
−300 −200 −100 0 100 200
Dimension 1
Di
m
en
sio
n 
2
100,000
150,000
200,000
-210
-220
-230
-240
-250
-260
dG (kcal/mol)
chimeric reads
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                  
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
                    
  
 
 
 
  
 
 
 
  
    
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
            
 
 
  
  
 
 
 
  
 
  
 
 
 
 
 
  
 
 
  
 
   
 
  
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
 
 
  
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
  
   
       
   
 
    
             
        
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
      
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
     
  
     
 
      
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
         
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
  
 
 
  
 
 
 
  
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
   
 
   
 
 
 
 
 
 
  
  
 
 
 
 
   
    
 
 
 
 
         
  
 
 
 
 
 
 
 
 
  
 
  
   
 
  
 
 
 
   
 
 
 
 
 
       
 
   
 
 
  
 
  
 
 
 
 
 
 
                    
 
 
 
    
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
  
 
 
 
  
 
 
    
 
 
   
 
 
   
 
 
      
 
        
 
 
 
 
 
          
 
 
    
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
   
  
  
  
  
   
 
 
 
 
   
 
   
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
  
 
 
 
 
 
 
       
 
 
   
 
 
 
 
 
            
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
   
 
  
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
 
 
  
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
            
 
 
 
 
 
 
       
 
 
   
 
 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
  
 
  
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
   
                
  
 
   
 
 
 
     
 
 
 
   
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    
 
 
 
    
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
    
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
    
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
  
  
 
     
 
     
 
 
 
     
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
  
           
 
          
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
  
  
  
 
 
 
 
  
 
  
 
 
 
 
 
  
  
 
 
  
  
 
 
 
  
 
 
 
  
 
 
 
                    
 
 
 
    
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
      
 
      
  
 
 
 
 
 
          
 
 
 
  
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
   
  
  
  
  
   
 
 
 
 
   
 
   
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
           
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
  
0 950
h
3' SL
New
0 272
CS
UAR DAR
10,807
71
 
 
 
 
 
 
 
 
 
 
             
  
             
            
   
    
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
            
  
   
   
 
  
    
 
           
  
    
   
                 
        
 
 
 
 
 
 
 
 
 
 
 
 
  
      
 
   
      
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
   
       
 
 
 
 
 
 
 
ORF
-300
-200
-100
-50
50 100 150 200
dG
 (k
ca
l/m
ol)
Chimeric reads (x1,000)
e fd
3' 
UT
R,
 1
0,
55
8-
10
,8
07
 n
t
5' UTR/Capsid, 1-250 nt 
UAR
DAR
CS
Newly identified
Rep. 1 Rep. 2 Rep. 3
Cont. 1 Cont. 2 Cont. 3
 0
 800
 0  2,000  4,000  6,000  8,000  10,000
5' CS viewpoint 3' CS
binding
Ch
im
er
ic 
re
ad
s c
ou
nt
 0
 700 3' CS viewpoint
 0  2,000  4,000  6,000  8,000  10,000
5' CS
binding
Nucleotide position
Individual structure
Minimal folding energy
 0
2,000
 0  2,000  4,000  6,000  8,000  10,000
nt 2-56: COMRADES
Ch
im
er
ic 
re
ad
s c
ou
nt
 0
 2,000 nt 2-56: Control
 0  2,000  4,000  6,000  8,000  10,000
Nucleotide position
Envelope
binding
En
ve
lop
e,
 9
80
-1
,2
30
 n
t
5' UTR/Capsid, 1-250 nt 
Rep. 1 Rep. 2 Rep. 3
Cont. 1 Cont. 2 Cont. 3
5' UTR - Envelope binding
aZiv et al., Fig. 3
b c
5’CS
3’CS
5’CS
miR-21
5’CS
V
N
M
L
cHP
5' CS
DCS-PK
5'
Zika virus
Human 
miR-21
A A A A A A G
A
A
A
U
C
C
G
G
A
G
G A
U
U
C
C
G
G
A
U
U
G
U
C A A U A U G C U A A A A
C
G
C
G
G
A
G
U A
G
C
C
C
G
U
G
U G
A
G
C
C
C
C
U
U U
G
G
G
G
G
C
U
U G A A G A G G C U G C
A G U
U G U
A G U
C A G
A C U A U U C G A U
3'
d e f
Control
COMRADES
mic
roR
NA tRN
A
sno
RN
A
vira
lRN
A
mis
cR
NA
snR
NA
mR
NA
pse
udo
RN
A
linc
RN
A
rRN
A
mtr
RN
A
0
20
40
60
80
CO
M
RA
DE
S 
ch
im
er
as
 /
co
nt
ro
l c
him
er
as
0
300
0
300
U1 snRNA
U1 snRNA
0 2,000 10,0008,0006,0004,000 12,000
ZIKV genome coordinate, nt
Control
COMRADES
ZI
KV
 - 
sn
RN
A 
ch
im
er
as
0 2,000 10,0008,0006,0004,000 12,000
0
300
0
300
Glu116
Glu116
Gly34 Gly34
Control
COMRADES
ZIKV genome coordinate, nt
ZI
KV
 - 
tR
NA
 ch
im
er
as
300
0
300
0
2,000 12,00010,0008,0006,0004,000
miR-21
miR-19 / miR-1323
miR-512
miR-515
ZIKV genome coordinate, nt
ZI
KV
 - 
m
iR
NA
 ch
im
er
as
Ziv et al., Nature Methods submission 17.06.2018 
  
Figure legends 176 
Fig. 1: COMRADES methodology. a, Experimental and computational workflows 177 
(upper and lower panels respectively). B: biotin; b, Virus-RNA pulldown, 178 
demonstrated by bioanalyzer profiles of ZIKV enriched RNA (upper panel) and input 179 
RNA (lower panel). c, Crosslinked-RNA pulldown, demonstrated by dot blot of biotin 180 
labelled RNA from COMRADES experiment. d, Crosslink reversal, demonstrated as 181 
described in (c). UVC: short-wavelength UV. e, % of chimeric reads in COMRADES 182 
and control libraries. Error bars represent standard deviation of 3 biological 183 
replicates. f, Probed interactions among cytoplasmic and mitochondrial ribosomal 184 
RNA subunits. rRNA: cytoplasmic ribosomal RNA; mtrRNA: mitochondrial ribosomal 185 
RNA. Error bars represent standard deviation of 3 biological replicates. g, Heat map 186 
of ZIKV RNA-RNA interactions. Each dot represents an interaction between the 187 
genomic coordinates on the x and y axes. Chimeras ligated in 5'-3' and 3'-5' 188 
orientations are plotted above and below the diagonal respectively. h, Zoom-in of a 189 
selected 1,500 nt region from (a). 190 
 191 
Fig. 2: The genomic structure of ZIKV inside human cells. a, Heatmap of RNA-192 
RNA interactions between cyclization elements. Rep: biological replicate; cont: 193 
control. b, Viewpoint histograms showing binding positions of the cyclization 194 
sequences along the ZIKV genome. Viewpoint regions are marked by dashed red 195 
lines. c, Probed interactions along the circular genome conformation. Colours 196 
representing numbers of non-redundant chimeric reads supporting each interaction. 197 
New: newly identified base-pairing. d, Heatmap of RNA-RNA interactions between 198 
the 5' UTR and the envelope coding region. e, Viewpoint histogram showing binding 199 
of nucleotides at position 2-56 along the ZIKV genome. f, Newly identified 5' UTR 200 
Ziv et al., Nature Methods submission 17.06.2018 
  
structure. Colour code as described in (c). cHP: capsid-coding region hairpin 201 
element; DCS: downstream of 5' cyclization sequence. g, Computationally predicted 202 
structures for nt 2288-3323. dG: folding energy. h, Clustering and prediction of 203 
alternative structures of nt 2288-3323. Colour code as described in (c).  204 
 205 
Fig. 3: Host-virus RNA-RNA interactions. a, Human RNA species interacting with 206 
the ZIKV genome. Error bars represent standard deviation of 3 biological replicates. 207 
b-d, Site specific base-pairing between the ZIKV genome and snRNAs (b), tRNAs 208 
(c), and specific miRNAs (d) in COMRADES libraries and controls. e, COMRADES 209 
determined base-pairing between ZIKV and miR-21. f, A model of the ZIKV 5' CS 210 
engaged in three separate functions. Ribosome and nascent polypeptide are marked 211 
in green. 212 
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Supplementary figure legends 226 
Supplementary Fig. 1: COMRADES assay development. a, Reverse transcription 227 
stalling assay indicating in vivo crosslinking positions in the 5.8S rRNA from cells 228 
treated with Psoralen (AMT), Psoralen-TEG azide, Psoralen-TEG biotin, or DMSO 229 
control. Arrows indicate stalling events. b, Bioanalyzer RNA profiles of ZIKV enriched 230 
(upper panel) or input (lower panel) RNA from non ZIKV-infected cells, as a control 231 
to Fig. 1b. c, Enrichment of ZIKV RNA measured by TaqMan PCR. Beta-actin serves 232 
as a control RNA. d-e, Non-cropped dot-blots corresponding to Fig. 1c-d. A shorter 233 
exposure is shown.  234 
  235 
Supplementary Fig. 2: COMRADES validation. a, In vivo detected interactions 236 
overlaid on the Ribovision 18S phylogenetic ribosomal RNA secondary structure. 237 
Colour-code is indicative of the number of supporting chimeras for each base-pair. b, 238 
Precision and sensitivity of ribosomal RNA base-pairing detection by COMRADES. 239 
Analysis is based on ZIKV enriched libraries, therefore the sensitivity of COMRADES 240 
is expected to be underestimated by this analysis. 241 
  242 
Supplementary Fig. 3: Intra-viral RNA interactions. a, Heat maps of ZIKV RNA-243 
RNA interactions in crosslinked libraries and controls. Chimeras ligated in 5'-3' and 244 
3'-5' orientations are plotted above and below the diagonal respectively. b, Arch plot 245 
representation of short and long-range RNA-RNA interactions along the ZIKV 246 
genome. Colours representing the number of non-redundant chimeric reads 247 
supporting each interaction. c, Distribution of RNA-RNA interactions by nucleotide 248 
distance between interacting chimeric partners. Left pie chart shows distribution of all 249 
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interactions; right pie chart shows distribution of interactions that span less than 250 
1,000 nucleotides. 251 
  252 
Supplementary Fig. 4: The genomic structure of ZIKV inside human cells. a, 253 
The ZIKV genome conformation with the highest chimeric-reads support. Colour 254 
code is indicative of the number of supporting chimeras for each base-pair. *: 255 
Regions with exceptionally low Shannon entropy; Vertical lines indicate long-256 
distance interactions. b, Viewpoint histograms showing binding positions of the 257 
cyclization sequences along the ZIKV genome in control libraries; related to Fig. 2b. 258 
Viewpoint regions are marked by dashed red lines. c, The non-circular ZIKV genome 259 
conformation. Colour code as described in (a). 260 
 261 
Supplementary Fig. 5: Folding entropy. a, Shannon entropy values calculated for 262 
each nucleotide along the ZIKV genome. Entropy may range from 0 to 13.4 bits; 263 
ZIKV coordinates are indicated by the position of genomic elements below. b, 264 
Inverse correlation between the degree of experimental support of base paired 265 
regions and their entropy. c, Shannon entropy values for a selected region of the 266 
ZIKV genome. d, Number of supporting chimeric reads for each base-pair shown in 267 
(c).     268 
  269 
Supplementary Fig. 6: Structures prediction. Computationally predicted 270 
structures for ~1,000 nucleotides regions along the ZIKV genome using randomly 271 
selected subsets of experimentally probed folding-constraints. Each structure is 272 
plotted as a dot according to its folding energy (dG) and experimentally supporting 273 
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evidence (chimera reads). Red dots indicating the structure with the lowest possible 274 
folding energy for each region.  275 
  276 
Supplementary Fig. 7: Clustering of structures. a, Clustering of structures based 277 
on degree of similarity, related to Fig. 2h. Example of structures are shown for 278 
selected fragments with a colour code representing the number of non-redundant 279 
chimeric reads supporting each interaction. b, Representation of the % of in vivo 280 
probed interactions in use in an ensemble of 5 structures, an ensemble of 1,000 281 
structures, or individual structures. Error bar represent standard deviation of 1,000 282 
structures.  283 
  284 
Supplementary Fig. 8: Co-clustering of non-shuffled and shuffled structures, 285 
related to Fig. 2h. a, Red scale indicates the number of chimeric reads supporting 286 
each non-shuffled structure. b, non-shuffled and shuffled structures, shown as white 287 
and black dots respectively.  288 
 289 
Supplementary Fig. 9: In vitro affinity of Ago2-miR-21 to the ZIKV 5' CS. a, 290 
Electrophoretic mobility shift assay (EMSA) of 5'-labeled miR-21 (lanes 1, 2) upon 291 
addition of ZIKV 5' CS (lane 2); and 5'-labeled ZIKV 5' CS (lanes 3-5) upon addition 292 
of miR-21 (lane 4) or of Ago2-miR-21 complexes (lane 5). b-h, In vitro measured 293 
affinities of Ago2-miR-21 to a wildtype ZIKV 5' CS (b), mutated 5' CS (c-d), a fully 294 
seed matched mutated 5' CS (e), mutated 5' CS with no cHP stem-loop (f), extended 295 
5' CS sequence containing the DCS stem-loop (g), and a short target perfectly 296 
complementary to the miR-21 seed (h). 297 
 298 
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Supplementary Fig. 10: miR-21 interaction with the ZIKV 5' CS. a, TaqMan PCR 299 
measurement of mature miR-21 expression level in wildtype cells and CRISPR/Cas9 300 
miR-21 deletion-clones. Values are normalized to spike-in control. b, Intracellular 301 
ZIKV RNA in miR-21 knockout and wildtype cells. c, Expression level of control and 302 
miR-21 psiCHECK-2 reporters upon treatment with miR-21 or control inhibitors. miR-303 
21 expression values denote for Renilla / Firefly luminescence signals. d, 304 
Intracellular ZIKV RNA in miR-21 inhibited and control cells. e-j, Intracellular levels of 305 
ZIKV envelope protein, measured by FACS. Representative experiment out of 3 is 306 
shown in (e-g); Gating strategy is shown in (h-j). NS1-AF488: Alexa Fluor antibody 307 
against ZIKV envelope protein. k, Replication of a ZIKV replicon carrying a wildtype 308 
5' CS or a 5' CS - 3' CS double mutant, pre-treated with miR-21 or non-targeting 309 
inhibitors. wt: wildtype; KO1-2: CRISPR/Cas9 miR-21 deletion-clones 1 and 2; cont: 310 
control; Error bars represent standard deviation of 3 (a, b, d), 4 (c), and 6 (k) 311 
biological replicates; Two-sided Student’s t-test p-value: ** <0.005; *** <0.0005; **** 312 
<0.00005; n.s.: non-significant.  313 
 314 
Online methods 315 
COMRADES. Each biological replicate was carried out independently on a different 316 
day, and included crosslinked sample, a control sample, and a non-crosslinked 317 
sample. 318 
  319 
Psoralen crosslink. JEG-3 cells (~50 million cells per experiment) were inoculated 320 
with ZIKV isolate PE243, at MOI: 2 TCID50/cell. 20 hours post inoculation cells were 321 
washed 3 times in HANKS solution and were incubated for 20 minutes with 0.4 322 
mg/ml Psoralen-triethylene glycol azide (psoralen-TEG azide, Berry & Associates) 323 
Ziv et al., Nature Methods submission 17.06.2018 
  
dissolved in PBS and diluted in OptiMEM I with no phenol-red (Gibco). Cells were 324 
irradiated on ice with 365 nM UV for 10 minutes using a CL-1000 crosslinker (UVP). 325 
Prolonged UVA irradiation should be avoided as it might decompose the azide 326 
moiety. Cells were lysed using RNeasy lysis buffer. Proteins were degraded by 327 
proteinase K (NEB) and RNA was purified using RNeasy midi kit (Qiagen). 328 
  329 
Viral RNA enrichment. Total RNA was mixed with an array of 50 biotinylated DNA 330 
oligos, 20 nucleotides-long each (IDT) designed to capture the ZIKV genomic RNA 331 
and was maintained at 37 °C for 6 hours rotating in the following hybridization buffer: 332 
500 mM NaCl, 0.7% SDS, 33 mM Tris-Cl pH 7, 0.7 mM EDTA, 10% Formamide. At 333 
the end of incubation Dynabeads MyOne Streptavidin C1(Invitrogen) were added 334 
and the RNA was incubated for additional 1 hour at 37 C. Beads were captured on a 335 
magnet and were washed 5 times with 2x SSC buffer containing 0.5% SDS. RNA 336 
was released from beads by degrading the DNA-probes with 0.1 units/µl Turbo 337 
DNase (Invitrogen) at 37 °C for 30 minutes. RNA was cleaned by RNA Clean & 338 
Concentrator (Zymo Research). 339 
  340 
Crosslink pulldown. RNA was fragmented to an average size of 100 nucleotides 341 
using RNase III (Ambion) and was cleaned by RNA clean & concentrator (Zymo 342 
Research). Copper-free Click reaction was carried at 37 °C for 90 minutes in the 343 
presence of 150 µM Click-IT Biotin DIBO Alkyne (Life technologies) and 0.5 units/µl 344 
Superase-In (Invitrogen). Reaction was terminated by RNA Clean & Concentrator 345 
(Zymo Research). Biotinylated RNA was pulldown using Dynabeads MyOne 346 
Streptavidin C1(Invitrogen) at the following reaction conditions: 100 mM Tris-Cl pH 347 
7.5, 10 mM EDTA, 1 M NaCl, 0.1% Tween-20, 0.5 unit/µl Superase-In. Beads were 348 
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captured on a magnet and were washed 5 times with 100 mM Tris-HCl pH 7.5, 10 349 
mM EDTA, 3.5M NaCl, 0.1% Tween-20. RNA was eluted by adding 95% 350 
Formamide, 10 mM EDTA solution and incubating at 65oC for 5 minutes. To avoid 351 
enrichment of small RNA chimeric reads that cannot be double-aligned to the 352 
reference ZIKV genome / Human transcriptome, RNA was size fractionated on 10% 353 
TBE-Urea gel and fragments corresponding to a size of 100-200 nucleotides were 354 
eluted overnight at 4 °C in 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 250 mM NaCl, 0.2% 355 
SDS. RNA was concentrated using RNA Clean & Concentrator (Zymo Research). 356 
  357 
Proximity ligation and crosslink reversal. At this stage, the RNA sample was 358 
divided in two. One half was used for proximity ligation and then crosslink reversal 359 
(i.e. Crosslink sample), while in the other half, crosslink reversal was done before 360 
proximity ligation (i.e. Reverse-control). We included an additional control containing 361 
an equimolar concentration (albeit a non-similar composition) of non-psoralen 362 
treated, non-crosslinked enriched RNA (i.e., Non-crosslinked sample). Before 363 
proximity ligation, the RNA was heated to 85 °C for 2 minutes and was cooldown 364 
rapidly on ice. Proximity ligation was done under the following conditions: 1 unit/µl 365 
RNA ligase 1 (New England Biolabs), 1x RNA ligase buffer, 50 mM ATP, 1 unit/µl 366 
Superase-in (Invitrogen), final volume: 200 µl. Reaction was incubated for 16 hours 367 
at 16 °C and was terminated by cleaning with RNA Clean & Concentrator (Zymo 368 
Research). Crosslink reversal was done by irradiating the RNA on ice with 2.5KJ/m2 369 
UVC. 370 
  371 
Sequencing library preparation. Library preparation was done as described in8 372 
with the following modifications: 6N unique molecular identifiers were added to the 5' 373 
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end of the 3' sequencing adapter; primers and adapters concentrations were lowered 374 
to match the low RNA input; Agencourt RNAClean XP beads (Beckman Coulter) 375 
were used for clean-up and size separation; pre-adenylated 5' and 3' adapters were 376 
used and all ligation reactions were carried without ATP to reduce ligation artefacts. 377 
All libraries and controls went through 13 PCR cycles using KAPA HiFi HotStart 378 
Ready Mix (KAPA Biosystems). PCR products were size-selected on a 1.8% 379 
agarose gel before loading on a HiSeq 1500 sequencer (Illumina). 380 
  381 
Cell culture. JEG-3 placental trophoblasts (ATCC) and Hela cells (ATCC) were 382 
cultured in Minimum Essential Medium supplemented with 10% fetal bovine serum, 1 383 
mM sodium pyruvate, GlutaMAX, non-essential amino acids and penicillin-384 
streptomycin. Vero cells (Sigma-Aldrich) were cultured in Dulbecco’s modified 385 
Eagle’s medium supplemented with 10% fetal bovine serum, GlutaMAX and 386 
penicillin-streptomycin. All cell lines were cultured in a humidified CO2 incubator at 387 
37 °C and were regularly examined to exclude mycoplasma contamination. 388 
  389 
Virus inoculation. ZIKV isolate PE243 was originated from Recife, Brazil in 2015. 390 
The virus was propagated in Vero cells and titer was determined by measuring the 391 
50% Tissue Culture Infective Dose (TCID50) in JEG-3 cells. For measurements of 392 
virus replication, JEG-3 or Hela cells were inoculated with ZIKV at MOI: 0.1 393 
TCID50/cell for three hours, after which cells were washed 3 times with PBS and 394 
supplemented with fresh growth medium. 24 hours post inoculation medium was 395 
removed, cells were washed 3 times with PBS and RNA was extracted using 396 
RNeasy kit (Qiagen). Virus copy number was determined using a TaqMan real-time 397 
PCR Assay (Primerdesign) and was normalized to GAPDH and ribosomal RNA. All 398 
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virus work was handled in a containment level 2 facility registered with the HSE 399 
under COSHH. 400 
  401 
Replicon assay. ZIKV wildtype and 5' CS - 3' CS double mutated replicons were 402 
described previously28. Replicon RNA was synthesized in vitro using MEGAscript T7 403 
Transcription Kit (Ambion). Replicon RNA was Capped using the ScriptCap m7G 404 
Capping System (Cellscript) and transfected to Hela cells using the TransIT-mRNA 405 
Transfection Kit (Mirus). Replicon levels were analyzed after 24-48 hours using a 406 
microplate luminometer (Promega) and normalized to baseline luminescence values 407 
measured at 6 hours post transfection. 408 
  409 
miR-21 knockout. JEG-3 cells were transfected with CAS9-gRNA riboprotein 410 
complexes using Lipofectamine RNAiMAX (Life technologies) according to the Alt-R 411 
CRISPR-Cas9 user guide (IDT). miR-21 knockout clone1 was generated using the 412 
following guide RNA: 5'-TCATGGCAACACCAGTCGATGGG-3' and contains a 413 
homozygous deletion at the positions 59841310-59841326 on chromosome 17 414 
(GRCh38/hg38 Assembly). miR-21 knockout clone2 was generated using a mixture 415 
of two guide RNAs: 5'-ATGTCAGACAGCCCATCGACTGG-3', 5'-416 
CTACCATCGTGACATCTCCATGG-3', and contain a homozygous deletion at 417 
positions 59841249-59841321 on chromosome 17. miR-21 knockout and control 418 
clones were validated by sanger sequencing and by TaqMan Advanced miRNA 419 
Assay targeting the mature miR-21 (Life Technologies). 420 
  421 
miR-21 inhibition. Hela cells were transfected with inhibitors targeting human miR-422 
21 or non-targeting control A (Power inhibitors, Exiqon) at a final concentration of 25 423 
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nM using Lipofectamine RNAiMAX. 6 hours post transfection medium was replaced 424 
and cells were inoculated with ZIKV or re-transfected with ZIKV replicons as 425 
described above. miR-21 inhibition was validated using a psiCHECK-2 reporter 426 
(Promega) carrying a fully complementary miR-21 site at the 3' UTR of a Renilla 427 
luciferase reporter along with a Firefly reporter to normalise transfection efficiency. 428 
Luminescence was assessed using the Dual-reporter assay (Promega) and 429 
normalized to control psiCHECK-2 without the miR-21 binding site. 430 
  431 
Gel-based Reverse Transcription Stalling (RTS) assay. RTS assay was 432 
performed as previously described29 using a Cy5-labeled primer targeting the human 433 
5.8S ribosomal RNA: 5'-Cy5-AAGCGACGCTCAGACAGG-3'. 434 
  435 
Dot blot analysis. 50 ng crosslinked RNA, or the indicated amount of 50 nt-long 436 
biotinylated standards were spotted on to a Biodyne B Nylon Membrane (Life 437 
technologies) and dried by baking at 80 °C for 10 minutes. Biotinylated RNA was 438 
detected using the chemiluminescent nucleic acid detection module Kit (Life 439 
technologies) and visualized using ChemiDoc MP Imaging System (Biorad). 440 
 441 
Purification of human Ago2 loaded with miR-21. Human Ago2 homogeneously 442 
loaded with miR-21 was prepared according to a published protocol30. Human 443 
 Ago2 was expressed in Sf9 cells using the Bac-to-Bac baculovirus expression 444 
system (Thermo Fisher Scientific). Sf9 cells were lysed and human Ago2 was 445 
purified by Ni-NTA affinity chromatography using a His tag. Human Ago2 was loaded 446 
with synthetic 5'-phosphorylated miR-21 (IDT), and the His tag was removed using 447 
Tobacco etch virus protease. Human Ago2 loaded with miR-21 was captured using 448 
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an antisense oligonucleotide (IDT), eluted, and purified by size exclusion 449 
chromatography on an ÄKTA FPLC (GE Healthcare Life Science). Protein 450 
concentration was measured using absorption at 280 nM with extinction coefficients 451 
obtained from the protparam tool (www.expasy.org) and from the ribotask 452 
oligocalculator (www.ribotask.com). 453 
  454 
Target RNA labelling. Synthetic RNA oligonucleotides (IDT) were radiolabelled at 455 
the 5'-end using gamma 32P ATP (Perkin Elmer) and T4 polynucleotide kinase 456 
(NEB), and purified by denaturing polyacrylamide gel and ethanol precipitation. RNA 457 
concentration was determined from absorption at 260 nM using extinction 458 
coefficients calculated with the ribotask oligocalculator (www.ribotask.com). 459 
  460 
Electrophoretic mobility shift assay (EMSA). Binding reactions were prepared in 461 
reaction buffer (28 mM Tris pH 8.0, 20 mM KCl, 80 mM KOAc, 1.6 mM Mg(OAc)2, 462 
0.5 mM TCEP, 0.004% NP-40, 0.01 g/l baker’s yeast tRNA) with a final volume of 20 463 
µl, and a final concentration of the labeled RNAs of 10 nM and of the non-labeled 464 
RNA or Ago2-miR-21 of 100 nM. Reactions were incubated for 10 minutes at room 465 
temperature and analyzed on a 15% acrylamide native gel in 0.5x TBE. 466 
  467 
Kd measurements. Binding experiments were conducted according to the protocol 468 
published in30. Ago2-miR-21 (0-200 nM) was incubated with 0.1 nM radiolabaled 469 
target in reaction buffer (28 mM Tris pH 8.0, 20 mM KCl, 80 mM KOAc, 1.6 mM 470 
Mg(OAc)2, 0.5 mM TCEP, 0.004% NP-40) with a total volume of 25 µl for 45 minutes 471 
at room temperature. Filter-binding was performed using a dot-blot apparatus (GE 472 
Healthcare Life Sciences) with Protran nitrocellulose membrane (Amersham, GE 473 
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Healthcare Life Sciences) and Hybond N+ nylon membrane (Amersham, GE 474 
Healthcare Life Sciences). Samples were applied with vacuum and washed with 50 475 
µl wash buffer (30 mM Tris pH 8.0, 100 mM KOAc, 2 mM Mg(OAc)2, 0.5 mM TCEP). 476 
After air drying, the membrane strips were used to expose phosphor screens (GE 477 
Healthcare Life Sciences) for visualization. Screens were imaged on a Typhoon 478 
phosphorimager (GE Healthcare Life Science) and signals were quantified with 479 
ImageQuant (GE Healthcare Life Sciences). Dissociation constants were calculated 480 
by fitting the data to a single site binding equation: 481 
! = #$%&[()*2][()*2] + ./ 482 
F = fraction target RNA bound, Bmax = maximal number of binding sites, [Ago2] = 483 
total concentration of the Ago2-miR21 complex, and KD = calculated dissociation 484 
constant, using Prism (GraphPad Software). For weakly binding RNAs Bmax was 485 
constrained to ≤1. 486 
  487 
Processing and visualization of sequencing data. Sequencing data were pre-488 
processed to combine FASTQ files of two sequencing lanes (cat) and to remove 489 
adapters (cutadapt). Paired end reads were merged by paired-end read merger 490 
(pear). UMIs were collapsed by collapse.py (T.D. Domenico, 491 
https://github.com/tdido). Chimeric reads were called and annotated with the hyb 492 
package31, using the command: 493 
  494 
hyb analyse in=data.fasta db=hOH7_and_Zika format=comp eval=0.001 495 
  496 
Hyb uses bowtie232 in local mapping mode to map reads to a transcriptome 497 
database and to identify chimeras, and it annotates the chimeras with RNA base-498 
Ziv et al., Nature Methods submission 17.06.2018 
  
pairing information generated by hybrid-min33. The transcriptome database used by 499 
hyb, “hOH7_and_Zika”, consists of human spliced mRNAs and noncoding RNAs 500 
described in14, and the genome sequence of the Zika virus (Zika virus isolate 501 
ZIKV/H.sapiens/Brazil/PE243/2015, complete genome). To evaluate the folding 502 
energy of chimeric reads, we used hybrid-min33 with default settings. We then 503 
randomly reassigned (shuffled) pairs of fragments found in chimeric reads, and 504 
repeated the folding energy analysis. The folding energies of experimentally 505 
identified and shuffled chimeras were compared by Wilcoxon test. 506 
  507 
Virus interaction heatmaps were plotted using Java Treeview34, such that color 508 
intensity represents the coverage of chimeric reads at every pair of positions. The 509 
first read of each pair is plotted along the X axis, and the second read along the Y 510 
axis. As a result, chimeras found in the 5'-3' orientation are shown above the 511 
diagonal, and chimeras in the 3'-5' orientation are below the diagonal. Viewpoint 512 
histograms were plotted with gnuplot, and arc plots were plotted with R-chie35. 513 
  514 
For every pair of positions (i, j) along the virus genome we calculated the 515 
COMRADES score, Cij: the number of chimeric reads that, when analyzed with the 516 
program hybrid-min with default settings, indicated base-pairing between positions i 517 
and j. We used COMRADES scores to calculate per-base Shannon entropy for each 518 
nucleotide position along the virus. Shannon entropy of position i is defined as: 519 
0123*45	7 = 	−9:(<7=)?*)@:(<7=),B=CD  520 
where n is the length of the genome (10,807 nt); and P(Cij) is 521 
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:(<7=) = 	<7= 9<7EBECD .G 	 522 
High entropy indicates flexible positions that may form multiple alternative base-523 
pairs, whereas low entropy indicates positions that always pair with the same 524 
nucleotide partner. We visualized RNA structures using VARNA36, where the colour 525 
scale represents the COMRADES score for each base pair. 526 
  527 
RNA structure prediction. For RNA structure predictions, we collected all potential 528 
base pairs with a non-zero Cij value, assembled sets of adjacent base pairs into 529 
uninterrupted stem structures, and calculated the base-pairing score of each stem as 530 
the sum of Cij values of individual base pairs. We then ranked these stem elements 531 
by their scores. In a preliminary analysis, we folded the 10,807 nt virus genome in a 532 
set of 50 overlapping 1,000 nt fragments, using the hybrid-ss-min program33. Each 533 
fragment was folded using a set of 250 top-ranked in vivo probed stem elements as 534 
folding constraints. Based on this preliminary analysis, we identified high-scoring 535 
stem-loop structures that were reproducibly predicted across multiple fragments, and 536 
we defined new fragment boundaries to prevent the disruption of these reproducible 537 
structural elements. As a result, we obtained fragment sizes that vary in size, but are 538 
approximately 1,000 nt long each. 539 
  540 
We then performed full folding analysis using the following fragment boundaries: 541 
5'UTR: 1-107, F1: 108-1275, F2: 1276-2287, F3: 2288-3323, F4: 3324-4521, F5: 542 
4522-5551, F6: 5552-6810, F7: 6811-7757, F8: 7758-8755, F9: 8756-9543, F10: 543 
9544-10379, 3'UTR: 10380-10807. 544 
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For each fragment, we assembled a set of folding constraints that represented the 545 
75 top-scoring stem elements within that fragment, we randomly shuffled this set of 546 
constraints 1,000 times, and we used the shuffled constraints for folding prediction 547 
by hybrid-ss-min. The resulting individual structures typically incorporate 25%-40% 548 
of these constraints. We recorded the folding energy of each structure, as predicted 549 
by hybrid-ss-min, and we used the sum of Cij values to calculate an overall score for 550 
each structure. To assemble the top-scoring full-genome structure shown in 551 
Supplementary Fig. 4a, we assembled the top-scoring structures for each coding 552 
sequence fragment (F1-F10), and the previously proposed structures of the 5' and 3' 553 
UTRs. An additional analysis of folding within and between the 5' and 3' UTRs is 554 
shown in Fig. 2a-c and Supplementary Fig. 4c. 555 
  556 
We also repeated the folding analysis with shuffled sets of 50-250 top-scoring 557 
constraints per fragment. This yielded similar results, but we found that either 558 
reducing or increasing the numbers of constraints tended to reduce the number of 559 
high-scoring structures. 560 
  561 
To explore the sets of alternative structures, we computed pairwise distances 562 
between structures as the number of positions with discordant base-pairing. This 563 
resulted in a 1,000 x 1,000 matrix of distances, which we then represented on a two-564 
dimensional surface using multidimensional scaling (using the R function cmdscale). 565 
Multidimensional scaling, also known as Principal Coordinate Analysis37, maps 566 
multidimensional objects (in this case, RNA structures) to a set of points on a plane, 567 
such that the distances between RNA structures are well-approximated by Euclidean 568 
distances between points, by minimization of a stress function: 569 
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 H23IJJK(&D, . . . , &B) 	= 	 L∑ (/7,= 	− 	N&7	−	&=N)@7O=CD..B PD/@ 570 
 571 
The RNA structure prediction pipeline can be downloaded from: 572 
https://github.com/gkudla/comrades 573 
 574 
Validation of ZIKV miR-21 interaction with an independent analysis pipeline. 575 
Alignment. The first read of each pair was processed using UMI-tools38 to extract 576 
the 6 nucleotide unique molecular identifier (UMI) at the start of the read. Processed 577 
reads were aligned using the STAR aligner39, reporting all reads in their original 578 
order (--outSAMtype BAM Unsorted --outSAMunmapped Within); only reporting 579 
unique alignments (--outFilterMultimapNmax 1); and reporting alignments to 580 
individual segments of chimeric reads (--chimOutType WithinBAM --581 
chimSegmentMin 20 --chimScoreJunctionNonGTAG 0 --582 
chimMainSegmentMultNmax 1). The reference consisted of the hg38 build of the 583 
human genome, combined with the genome sequence of the PE243 strain of the 584 
Zika virus. Each read of the pair was aligned separately to avoid preferencing 585 
alignment to the same genomic locus. 586 
For each library, the pair of BAM files were collated and pair information was fixed 587 
using samtools40. PCR duplicates were removed on the basis of their UMIs, using 588 
UMI-tools in paired mode. 589 
  590 
Detecting significant interactions. We considered the "interaction space" between 591 
the human and Zika genomes, consisting of pairs of 1 kbp bins (one on each 592 
genome). For each replicate library in each condition (crosslinked and reversed 593 
control), we counted the number of read pairs with one read in each bin using 594 
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diffHic41. This yielded a count matrix that was normalized using the trimmed mean-595 
of-M-values method42 to correct for composition biases, under the assumption that 596 
most read pairs mapping across the Zika and human genomes was caused by non-597 
specific ligation. We then applied the quasi-likelihood framework in edgeR43 to test 598 
for significant differences between the read pair counts for crosslinked and the 599 
reverse control. This was performed using an additive design matrix that blocked on 600 
the batch to reflect the paired-sample design of the experiment. 601 
Robust empirical Bayes shrinkage44 was also used to stabilise the dispersion 602 
estimates in the presence of limited replication. Bin pairs were aggregated into 603 
clusters based on whether they overlapped the same human gene 604 
Test statistics were combined for each gene-Zika interaction using Simes' method45 605 
prior to applying the Benjamini-Hochberg method. Interactions that were significantly 606 
enriched in COMRADES over the reversed control were defined at a false discovery 607 
rate threshold of 5%. 608 
 609 
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